Conjugate between a modified superantigen and a target-seeking compound and the use of the conjugate
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 5, 2007
Grant Date -
N/A
app pub date -
Jun 7, 1995
filing date -
Jul 11, 1994
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method for the treatment of a disease in a mammal by administering a therapeutically effective amount of a conjugate comprising a biospecific affinity counterpart and a peptide, wherein the peptide contains an amino acid sequence that is derived from staphylococcal enterotoxin A, binds to a V.beta. of a T cell receptor, and has a D227A mutation so that the peptide has a modified ability to bind to MHC class II antigens.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully